PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Mycophenolate mofetil - Dermatology indications
PAD Profile : Mycophenolate mofetil - Dermatology indications
Keywords :
myositis, severe psoriasis, severe atopic dermatitis,/eczema, autoimmune bullous dermatoses, SLE, mycophenolic sodium, mycophenolic acid, RMOC, national shared care
Brand Names Include :
Arzip, CellCept, Myfortic, Myfenax, Ceptava
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Rheumatology indications
- Gastroenterology indications
- Haematology Indications
- Hepatology Indications
- Neurology indications
- Uveitis
- Oral disease indications
- Renal indications
- Respiratory disease indications
- Scleritis
Additional Documents
Type
Document
Review Date
Shared Care
Shared Care
01 January 2025
Shared Care
Shared Care
Committee Recommendations
Date
Committee Name
Narrative
07 December 2022
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol (with local adaptations) for mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)
Associated BNF Codes
13. Skin
13.05.03. Drugs affecting the immune response